Clinical Report: Dry Eye Best Practices Must Surpass Standards of Care
Overview
Revise to better define the terms 'standard of care' and 'best practices' with examples.
Background
Dry eye disease is a prevalent condition that significantly impacts patients' quality of life. Recent advancements in research and technology have led to improved diagnostic methods and treatment options. Understanding the difference between standard of care and best practices is crucial for eye care professionals to provide optimal patient care.
Data Highlights
No specific numerical data provided in the article.
Key Findings
- Every eye specialist should routinely assess for DED during examinations.
- Best practices include using validated questionnaires like SPEED and OSDI to evaluate symptom severity.
- Tear osmolarity testing is essential for diagnosing covert DED, especially in asymptomatic patients.
- Advanced practices should incorporate comprehensive assessments, including meibomian gland evaluation and ocular surface staining.
- Fluorescein is the standard dye for staining, but lissamine green may provide additional diagnostic information.
Clinical Implications
Eye care professionals must integrate best practices into their routine assessments to ensure accurate diagnosis and effective treatment of DED. Utilizing advanced diagnostic tools can help identify patients with covert DED, leading to better management strategies.
Conclusion
Adopting best practices in dry eye management is essential for improving patient outcomes. Continuous education and adaptation to new diagnostic techniques will enhance the quality of care provided to patients with DED.
References
- Jessica H. Mathew, OD, PhD, FAAO, Contact Lens Spectrum, 2015 -- Contact Lens Practice Pearls
- Katherine M. Mastrota, MS, OD, Contact Lens Spectrum, 2016 -- DRY EYE DX AND TX
- Contact Lens Spectrum, 2024 -- CONTACT LENS CLINICAL CONTROVERSIES 2024
- Optometric Management, 2023 -- CLINICAL: Dry Eye Recommendations
- TFOS DEWS III: Diagnostic Methodology, ScienceDirect, 2025 -- TFOS DEWS III
- Frontiers, 2024 -- Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials
- Ophthalmology and Therapy, 2025 -- Dry Eye Disease Management Via Technological Methods: A Systematic Review and Network Meta-analysis
- TFOS DEWS III: Diagnostic Methodology - ScienceDirect
- Frontiers | Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials
- Dry Eye Disease Management Via Technological Methods: A Systematic Review and Network Meta-analysis | Ophthalmology and Therapy | Springer Nature Link
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







